Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

UniSens

Financiado

Universal GPCR Activity Sensor for Next Generation Drug Discovery

This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic... ver más

31/10/2027

ISAR BIOSCIENCE Gm...

3M€

Presupuesto del proyecto: 3M€

Líder del proyecto

ISAR BIOSCIENCE GmbH No se ha especificado una descripción o un objeto social para esta compañía.

Ver 8 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-30

HORIZON-EIC-2023-PATHFINDEROPEN-01-01: EIC Pathfinder Open Scope:

I+D

Cerrada hace 1 año

0% 100%

8 Participantes

ISAR BIOSCIENCE GmbH

957.35K€ | Lider

INSERM

134.73K€ | Participante

STICHTING VU

405.90K€ | Participante

INNOVATIVE BIOIMAGING SRO

81.98K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

SAF2012-33481 EXPANDIENDO EL ESPACIO FARMACOLOGICO: NUEVAS HERRAMIENTAS PA... 117K€ Cerrado

K4DD Kinetics for Drug Discovery (K4DD) 21M€ Cerrado

EUC²LID European Lead Factory 197M€ Cerrado

PTQ-16-08394 Plataforma de desarrollo de fármacos para GPCRs basada en cr... 83K€ Cerrado

SAF2014-53977-R HERRAMIENTAS DE RMN PARA EL DESARROLLO DE UNA PLATAFORMA PAR... Cerrado

PID2019-109240RB-I00 MODULACION DE LOS HETEROMEROS DE RECEPTORES ACOPLADOS A PROT... 236K€ Cerrado

Duración del proyecto: 48 meses Fecha Inicio: 2023-10-30
Fecha Fin: 2027-10-31

Líder del proyecto

ISAR BIOSCIENCE GmbH No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 3M€

Descripción del proyecto This project by a consortium of academic labs and small biotech companies concerns a new key innovation for the development of drugs targeting G protein-coupled receptors (GPCRs). GPCRs are the most important class of therapeutic targets, both for current drugs and those under development, covering about a third of the €1.2 trillion pharmaceutical market. Recent research has revealed that GPCRs do not function as simple on/off switches but instead can adopt multiple conformations leading to complex textures of downstream effects. Functionally selective drugs modulate the GPCR structure to stimulate certain downstream pathways over others. In the search for this next generation of better drugs, the pharmaceutical industry currently employs multiple (10+) distinct GPCR assays, performed in non-identical cellular contexts, and misleading readouts from this approach contribute significantly to costly drug failure. Here we propose a radically new single-assay technology platform that will enable detection and functional classification of drug candidates with superior confidence compared to today's approaches. Its unique design supports streamlined drug discovery from the test tube to the native disease-relevant cell, as well as the capacity to efficiently harness artificial intelligence (AI) in the design of better drugs. The technology is based upon highly informative fluorescent sensor reagents that react to different receptor conformations with subtle, flexible changes in their structure. In this Pathfinder project, our main objective is to demonstrate that the conformational fingerprints generated by these sensors correlate to specific cellular signalling profiles, i.e. GPCR activity states (proof of principle). We believe that the UniSens platform will become the standard tool for early drug development and could be a game-changer in the search for safer, more effective drugs.

Conecta tu I+D

Entra hoy

¿Olvidó su contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores